Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engineered PBSC Transplant for Myeloid Malignancies
NCT00049634Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2002
- Primary completion
- Feb 2007
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), sponsored by Fred Hutchinson Cancer Center. Started Jan 2002; status: completed.
02
Drugs
allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT00049634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049634.